In a study of advanced melanoma, it was demonstrated that the combination of local chemotherapy (nitrogen mustard alkylating agent melphalan) and anti-CTLA-4 improved response rate and progression-free survival (PFS) through enhancing the infiltration of T cells to the tumor site (27). This evidence concerns the gene CTLA4 and melanoma.